Elena Volodicheva

Publications by Year

Research Areas

Lymphoma Diagnosis and Treatment, Platelet Disorders and Treatments, Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Blood groups and transfusion

Most-Cited Works

• → Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study(2020)333 cited
• → Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial(2023)80 cited
• → Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study(2019)32 cited
• → Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma(2014)12 cited
• → Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma.(2014)6 cited
• → Current Quality-of-Life Aspects in Patients with Classical Ph-Negative Myeloproliferative Neoplasms in the Russian Federation: Results and Discussion of the National Observational Program MPN-QoL-2020(2022)5 cited
• → Multiple Myeloma in Russia (First Results of the Registration Trial)(2017)5 cited
• → Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)(2015)5 cited
• → Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: The first results(2016)5 cited
• → Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma(2019)5 cited